Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system with a strong genetic component. Several lines of evidence support a strong role for genetic factors influencing both disease susceptibility and clinical outcome in MS. Identification of genetic variants that distinguish particular disease subgroups and/or predict a severe clinical outcome is critical to further our understanding of disease mechanisms and guide development of effective therapeutic approaches. We studied 1470 MS cases and performed a genome-wide association study of more than 2.5 million single-nucleotide polymorphisms to identify loci influencing disease severity, measured using the MS severity score (MSSS), a measure of clinical disability. Of note, no single result achieved genome-wide significance. Furthermore, variants within previously confirmed MS susceptibility loci do not appear to influence severity. Although bioinformatic analyses highlight certain pathways that are over-represented in our results, we conclude that the genetic architecture of disease severity is likely polygenic and comprised of modest effects, similar to what has been described for MS susceptibility, to date. However, a role for major effects of rare variants cannot be excluded. Importantly, our results also show the MSSS, when considered as a binary or continuous phenotype variable is by comparison a stable outcome.
Introduction
Multiple sclerosis (MS (MIM 126200)) is an inflammatory demyelinating disease of the central nervous system that has an important neurodegenerative component and results in the accumulation of neurological deficits in most patients. 1 An important feature of the disease is the heterogeneity of its clinical manifestations that includes a wide range of cognitive and functional disability; in general, disability increases with disease duration. Through recent advances in biomedical research, it is evident that both genetic and environmental factors contribute to MS susceptibility. 2 The search for genetic risk factors affecting susceptibility to MS has been particularly successful, but it is not yet clear whether these susceptibility alleles or other genetic variants influence the course of MS. Currently, the genetic architecture of MS susceptibility includes one locus with a very strong effect on risk-the major histocompatibility complex-and over a dozen susceptibility loci with modest effects such as IL7RA, IL2RA, CLEC16A, CD58, CD6, IRF8, KIF21B, TMEM39A and TNFRSF1A. 1, [3] [4] [5] Interestingly, concordance in families for early and late clinical features indicates that, in addition to susceptibility, genetic variation may influence disease course and other clinical phenotypes. [6] [7] [8] The clinical course of MS may also differ between ethnic groups. 9 In the MS animal model, experimental autoimmune encephalomyelitis, multiple loci modulate specific phenotypes such as topographic location of lesions in the brain or spinal cord as well as the nature and severity of the inflammatory response. [10] [11] [12] [13] Given these observations and our current understanding of the genetic architecture of human traits, it is likely that many genetic variants of modest effect have a role in influencing the course of MS.
The gradual accumulation of disability over the course of MS and the limited availability of longitudinal assessments of disability has hampered efforts to delineate specific biological mechanisms contributing to disease course. However, one method provides a measure of clinical disability and incorporates the important variable of disease duration: the MS severity scale (MSSS). 14 The MSSS is a probabilistic algorithm that captures disease severity by adjusting disability (as measured by the Expanded Disability Status Scale (EDSS)) at a point in time for disease duration. This method has been shown to be more powerful than alternative measures of disease severity. 14 The MSSS score for an individual reflects the expected percentage of patients in the reference population (9892 patients from 11 countries), with a lower EDSS score for comparable disease duration; it is an attractive measure for MS severity as it requires information from a single time point and is applicable to all MS patients regardless of disease course (that is, whether the patient has a progressive component to his/her illness). Several studies support the validity of MSSS; [14] [15] [16] nonetheless, while this method is robust, it does not capture all aspects of disability in MS.
To date, a handful of studies have explored the genetic component contributing to MS progression. Several studies have investigated specific candidate genes and/ or MS susceptibility loci using various measure of disease severity, [17] [18] [19] [20] and two genome-wide association (GWA) scans of MSSS have been published. 21, 22 However, there is no confirmed MS severity locus at this time, and our understanding of the neurodegenerative disease component of MS remains limited. Thus, identifying genetic variation with effects on the severity of MS could be instrumental to further our understanding of disease mechanism(s) and contribute to clinical prognostic algorithms. Here, we present a comprehensive investigation of MSSS using 1470 MS subjects and analysis of genotypes derived from more than 2.5 million singlenucleotide polymorphisms (SNPs) (see Figure 1 ). We provide a methodological framework for investigating MSSS to address analytical challenges that are present for studies using this clinical outcome.
Results
A total of 1470 MS patients, recruited from three clinical centers (Table 1; Table 1 ); therefore, random-effects meta-analyses were pursued. Given the distributional differences in MSSS by recruitment center (Figure 2 ), we explored three phenotypic outcomes based on MSSS, with an aim of determining the most suitable statistical model for the data. MSSS was classified as follows (see Materials and methods; The stability of the estimators from random-effects meta-analyses for each MSSS outcome was evaluated using 100 bootstraps based on an augmented testing data set of 1000 SNPs (see Materials and methods). The significance rank of each SNP in the augmented testing data set was noted for each meta-analysis and we compared the percentage that were present among the top-ranking SNPs from the bootstrapped analyses at the top 1% (N ¼ 10), 5% (N ¼ 50) and 10% (N ¼ 100) SNPs when ranked by significance. The meta-analyses were comparably stable ( Figure 3) ; on average, at least one of the SNPs among the top 1% (top 10 SNPs) in the augmented data set was also ranked among the top 1% (top 10 SNPs) across all bootstrapped analyses regardless of phenotypic outcome. Similarly, approximately 12 and 30 SNPs from among the top 5% (top 50 SNPs) and 10% (top 100 SNPs) ranked SNPs in the augmented data set were also ranked among the top 5 and 10% in the bootstrapped results across phenotypic outcomes, respectively. We subsequently report from all three meta-analyses, as each phenotype targets a different definition of MS severity, and may highlight relevant information not present in any single analysis. A total of 5267 genes had associations at Po0.05 level; however, a third of the results from all three meta-analyses overlap ( Supplementary Figures 1 and 2) .
The most significant associations for SNPs within genes from each meta-analysis are presented in Table 2 . Importantly, no association met GWA significance criteria (Po5 Â 10 
À4
; EXTREME MSSS, rs8056098: OR ¼ 0.74, P ¼ 5.5 Â 10
; CONTINU- ). We compared our results directly with those reported in a previous independent GWA investigation of MSSS 21 ( ). No overlap with other published GWA results was observed based on the stringent criteria (Po0.0001). 22 Associations lower than Po10 À5 for any classical human leukocyte antigen region SNPs (total n ¼ 8701 examined) with any of the three MSSS phenotypes were not present; in particular, no class II region SNPs showed strong evidence of association (data not shown). MICB (specifically, rs2855814-an intronic SNP) was the only gene with Po0.0001 in any of human leukocyte antigen region analyses (data not shown).
Two pathway-based investigations of significant genes (Po0.001; N ¼ 441) from the union of the three metaanalyses were also conducted (see Materials and methods). Based on pathways curated in the Kyoto Encyclopedia of Genes and Genomes database, [23] [24] [25] there was significant (Po0.001) over-representation of genes involved in several Kyoto Encyclopedia of Genes and Genomes pathways, including: calcium signaling, natural killer cell-mediated cytotoxicity, antigen processing and presentation, axon guidance and Wnt signaling A full colour version of this figure is available at the Genes and Immunity journal online. Figure 3 Estimator stability for each MSSS meta-analysis: percent concordance of top-ranking SNPs in the testing data set and across the 100 bootstrapped data sets. To determine which meta-analysis of the phenotypic outcome was most appropriate given the distribution of MSSS (see Figure 2 ), the stability of the estimator was evaluated using bootstrap. An augmented data set of 1000 randomly selected SNPs from among the union of SNPs (N ¼ 196 771 SNPs) that showed a significant association (Po0.05) in any of the three meta-analyses. One hundred bootstrap replicates were generated and the meta-analyses were performed (logistic and linear regression as appropriate) for each SNP in each of the 100 bootstrapped data sets. The ranking of each SNP in the original augmented data set was compared with its ranking in each of the 100 bootstrapped data sets. The aim was to determine if a specific phenotype showed greater stability among its top 1% (10), 5% (50) and 10% (100) SNPs. The application of a random-effect metaanalysis proved to be consistently stable across the phenotypic outcomes; therefore, all three meta-analytical results were considered equally. A full colour version of this figure is available at the Genes and Immunity journal online.
( Table 5) . Similarly, when Gene Ontology terms were investigated, there was significant enrichment of terms associated with neuronal processes, calcium ion transport and interferon a/b receptor binding, among other terms (Supplementary Figure 3) .
Discussion
MS is a common cause of neurological disability in individuals of European descent. 26 Previous efforts to investigate the underlying genetic component contributing a SNP genotypes were coded as a continuous variable (0-2 range) to reflect the imputation probability of the presence of the minor allele (where 0 indicates the absence of the minor allele). Random-effects meta-analyses adjusted for gender and cohort of origin were conducted for each phenotype (logistic regression for the binary outcomes: median MSSS and extreme MSSS; linear regression for the continuous MSSS outcome). Genes with only a single significant association (Po0.05) were ignored. Only SNPs located within genes are shown. All genes, alleles and SNP function were retrieved from the National Center for Biotechnology Information's (NCBI) dbSNP browser. Basepair locations are specified with respect to the forward (+) strand of the NCBI Build 37.1. to MS progression and severity have been limited by small sample sizes, clinical heterogeneity and availability of genotypic information. Herein, we report a genomewide investigation of MS disease severity characterized by the MSSS using over 2.5 million SNPs in 1470 MS patients of European descent. The MSSS is a probabilistic algorithm that relates disability scores (EDSS) to a distribution of patients with comparable disease duration.
14 However, the true distribution of MSSS is not known, although it is traditionally treated as having a normal distribution. This presents an interesting analytical challenge for selecting an appropriate parametric model for MSSS inference.
Given the significant differences in the distribution of MSSS by recruitment site, we investigated the stability of estimators for three phenotypic outcomes: (1) dichotomizing MSSS by the overall minimum (MEDIAN MSSS); (2) dichotomizing MSSS by extreme phenotypes (EXTREME MSSS); (3) and as a continuous variable (CONTINUOUS MSSS). The aim was to determine which of the three phenotypic outcomes was most appropriately investigated using a random-effects meta-analysis. Random-effects meta-analysis allows for heterogeneity across studies due to inherent differences and/or differential biases, unlike fixed-effects models that assume a single common effect that underlies each study in the meta-analysis. As a general rule, a random-effects meta-analysis is generally more conservative, generating wider confidence interval and larger P-values. 27 To determine the most suitable random-effects meta-analysis, bootstrap was used to generate 100 data sets for a subset of 1000 SNPs, which were randomly selected from among all SNPs that showed some level of association (Po0.05) with one of the MSSS outcomes. We compared the rank of the randomly selected SNPs in the augmented data set to the rank across the bootstrapped data sets. We hypothesized that a more stable model would have a higher percent concordance among the top-ranking SNPs. Surprisingly, the three random-effect meta-analyses were equally stable. As each analysis is based on a slightly different hypothesis, we considered results from all three analyses. Figure 4 Manhattan plots for the random-effects meta-analyses adjusted for cohort and gender. A full colour version of this figure is available at the Genes and Immunity journal online.
Median MSSS
The most significant result based on gene association for each phenotypic outcome was consistent across all meta-analyses (Tables 2 and 3 ). Interestingly, biological evidence supports a potential role for some of these candidates in MS disease severity. For example, PTPRD (protein tyrosine phosphatase (receptor type) d) on chromosome 9 encodes a transmembrane protein involved in neuronal differentiation, 28, 29 neurite outgrowth 30 and excitatory synapse formation. 31 In murine models, PTPRD has been shown to regulate learning 32 Genes listed have at least one SNP significantly associated at Po0.001 in at least one of the MSSS meta-analyses. Genes were excluded if there was only one significant SNP association (Po0.05) in any meta-analysis. This shows overlapping associations (with gene) reported in a previous independent GWAS of MSSS (Po0.0001). 21 and motoneuron axon guidance. 33 PTPRD has recently been identified as a susceptibility locus for restless leg syndrome. 34 Interestingly, there is clinical evidence that restless leg syndrome is more prevalent in MS patients, particularly those with greater disability. 35, 36 TRIM2 on chromosome 4 encodes a protein that localizes to cytoplasmic filaments with a TRIM motif (three zinc-binding domains) and participates in axon outgrowth during development. TRIM2 has been shown to participate in neuronal plasticity, 37 axon initialization 38 and ubiquitination of the neurofilament light subunit.
39
TRIM2-deficient mice have greater levels of neurofilament light subunit in axons and resulting axonal swellings in the cerebellum, retina, spinal cord and cerebral cortex, leading to progressive neurodegeneration with juvenile-onset tremor and ataxia.
YWHAG (14-3-3g protein) on chromosome 7 encodes a member of a highly conserved 14-3-3 family of proteins that mediate signal transduction. YWHAG is predominantly expressed within neurons 40 and astrocytes. 41 In neurons, 14-3-3g protein appears to contribute to neuronal vulnerability during oxidative stress 42 and increased levels promote astrocyte survival, whereas decreased levels result in increased apoptotic loss under ischemia. 43 YWHAG resides on chromosome 7q11.23, along with several genes, and haploinsufficiency of this region results in William-Beuren syndrome, which includes a specific mental retardation profile, distinctive dysmorphic features and supravalvular aortic stenosis. 44 Interestingly, zebrafish knocked down for YWHAG have reduced brain size and an increased diameter of the heart tube. 45 Finally, GRIN2A encodes a member of ionotrophic glutamate-gated ion channels, the NR2A subunit. A previous GWA study of MSSS identified GRIN2A as a candidate, albeit not the exact SNPs we observed (Table 4) . 21 Further, limited data available through HapMap (http://hapmap.ncbi.nlm.nih.gov/) cannot fully discern whether strong linkage disequilibrium exists between the associated SNPs identified in both studies. However, there is accumulating evidence for the involvement of glutamate receptors in MS and related animal models, including preliminary evidence showing increased expression of NR2A subunit in central nervous system tissue from encephalomyelitis rats. 46, 47 NR2A is expressed primarily in the neocortex and other forebrain structures, 48, 49 and is also present on oligodendrocytes. [50] [51] [52] NR2A complexes with other N-methyl D-aspartate receptor subunits to form heterodimers, of which there are several. However, NR2A-containing heterodimers are the most stable and do increase in prevalence at synaptic surfaces as the neuron matures. 53 Furthermore, genetic variation within GRIN2A has been associated with autism, 54,55 schizophrenia 56 and modifying age of onset in Huntington's disease. [57] [58] [59] We note that GRIN2A is a large gene (stretching 421 kb per HapMap: http://hapmap.ncbi.nlm.nih.gov/), which skews the likelihood of replicating an association within the gene. Nonetheless, our evidence is consistent with a previous MSSS GWA study, 21 making this locus a viable candidate for further investigation.
A special emphasis was placed in the current investigation on 21 previously established MS susceptibility loci. 5, 60 None of the reported variants showed any The union of genes with at least one significant SNP association at the Po0.001 level. Genes with one SNP association at the Po0.05 level were excluded. Of the 441 genes submitted for analysis, 424 were incorporated for analysis using a hypergeometric test to compare the submitted list to a reference of all human genes using WebGestalt v.2 (http://bioinfo.vanderbilt.edu/webgestalt/). Genes excluded were primarily predicted/hypothetical loci with no known function. The analysis was limited to KEGG pathways where at least two genes were present in the submitted list.
evidence for association with severity (Supplementary  Table 1 ). However, over 1100 SNPs in 13 of the 21 susceptibility loci had an association with MSSS at Po0.05 in at least one of the three meta-analyses (Supplementary Table 2 ). Given the importance of these particular genes in the development of MS, further work will be needed to fully characterize their role, if any, in disease severity and progression. MGAT, reported recently as associated with MSSS, 22 was not replicated in our study. Finally, current results do not support a strong role for human leukocyte antigen influences on MSSS, and are consistent with previous reports. 21, 22 An extensive and conservative power assessment of the three MSSS phenotypes investigated in this analysis was conducted to guide interpretation of results, given the number of statistical tests performed and that no observed associations met genome-wide significance (P41 Â 10
À6
). We assumed a population risk of 0.0001 for each phenotype. For CONTINUOUS MSSS (mean ¼ 4.1, s.d. ¼ 2.9, N ¼ 1470), power was low to detect most associations at Po1 Â 10
À5
, with the exception of moderately large effects (absolute b40.6) for more common variants (MAF 40.30). For Po1 Â 10 Figure 6) . Despite this being one of the largest investigations of MSSS performed, to date: that adequate power was available to detect some of the reported associations with P41 Â 10
À6
and that we hypothesized larger genetic effects would be responsible for associations with disease severity, it is important to note that power to detect modest associations for less common variants was quite limited. Similar to GWA study for susceptibility loci in MS, it appears that genetic influences on severity as characterized by the MSSS are likely to be polygenic and modest. Our results are also consistent with a role for major effects of yet unidentified rare variants. Further and much larger studies are needed to fully characterize the genetic component in MS that influences disease severity and progression.
Materials and methods
Study population A total of 1655 MS patients of European descent were initially included for analysis (as described previously). 3 All subjects met the McDonald criteria for the diagnosis of MS. 61 The MS subjects were recruited from three clinical sites: 453 cases from the UK (IMSGC UK) and 342 cases from the US (IMSGC US); the remaining 860 MS patients were recruited at Partners MS Center in Boston, MA (BWH). There were no overlapping subjects among the three recruitment sites. Stringent assessment of population stratification outliers were conducted for each cohort. 3, 62 Appropriate institutional review boards approved all studies and written informed consent was obtained from all participants. Individuals with disease duration less than a year were excluded from the analysis, resulting in a final study population of 1470 MS cases (Table 1) .
Genotyping and imputation MS subjects recruited through the IMSGC were genotyped on the Affymetrix platform using the GeneChip Human Mapping 500K Array set. 62 The BWH MS subjects were genotyped on the Affymetrix Genomewide Human SNP Array 6.0 (GeneChip 6.0). 3 Conservative quality control measures were imposed on each data set before imputation (as described previously). 3, 62 The data sets were imputed to a common panel of 2.56 million SNPs using the MACH algorithm with HapMap data for Utah residents of northern and western European ancestry as the reference. 3 The probabilistic dosages rather than hard genotype calls were used in this investigation, to allow for imputation uncertainty at each locus. Non-autosomal SNPs were excluded, as well as SNPs with an imputation quality score less than 0.3 and an MAF o1%. MAF was calculated by summing the imputed genotypes for each SNP and dividing by twice the number of individuals in the study. A total of 2 151 258 SNPs were included for the analysis of both the MEDIAN and CONTINUOUS outcomes, and 2 110 417 SNPs for the EXTREME analysis (due to increased number of SNPs with MAF o1% as a result of a reduced study population (N ¼ 875); Table 1 ).
MSSS
MSSS was calculated using EDSS and disease duration, which was defined as the elapsed time (in years) between the first symptom and EDSS assessment. The distribution of MSSS varied by recruitment site (Figure 2) , with an overall bimodal distribution with the minimum at an MSSS of 5 ( Figure 2) . As a result, MSSS was also categorized into two binary variables, with the less severe category as the reference. MSSS was first dichotomized by the minimum of overall bimodal distribution (the expected median 14 ). The MEDIAN MSSS variable was defined by MSSS p5 vs 45 (Table 1) . MSSS was also dichotomized to reflect the extremes of the disease severity. The EXTREME MSSS variable was defined by MSSS o2.5 vs X7.5 (Table 1) . MSSS was also treated as a continuous variable: CONTINUOUS MSSS.
Analytical methods An analysis of variance (one-way analysis of variance) test compared mean MSSS across the three recruitment sites, and MSSS significantly differed. Given the observed MSSS heterogeneity among the three recruitment sites, it was important to consider which phenotypic outcome was most appropriate for investigation using a random-effects meta-analysis. The stability of the estimators for each MSSS outcome (MEDIAN, EXTREME and CONTINUOUS) was evaluated using bootstrap. 63 Bootstrap is a computational procedure where the original data set is resampled with replacement, creating a synthetic data set. The objective is to emulate the process by which observations are selected into a study.
First, for each outcome, a random-effects meta-analysis was conducted with the cohort of origin as the random-effect, and gender and genotype as fixed-effects using the glmmML function in the R package glmmML v.0.81-6 (http://www.cran.rproject.org/web/packages/ glmmML/index.html/). A logistic model was used for the binary outcomes (MEDIAN and EXTREME) and a linear model for the continuous outcome (CONTINU-OUS). Second, a random subset of 1000 SNPs were selected from among the union of significant SNPs (Po0.05; N ¼ 196 771 SNPs) from all three meta-analyses to create an augmented testing data set. One hundred bootstrap replicates were generated and the metaanalyses were performed (logistic and linear regression as appropriate) for each SNP in the augmented testing data set in each of the 100 bootstrapped data sets. The ranking of each SNP in the augmented data set was compared with its ranking in each of the 100 bootstrapped data sets. The aim was to determine if a specific phenotype showed greater stability among its top 1% (10), 5% (50) and 10% (100) SNPs when ranked by significance. For example, if a greater percentage of top 10 SNPs from the augmented data set were consistently present among the top 10 most significant SNPs in the bootstrapped data sets for a specific phenotypic outcome, it would suggest that the model for that phenotype was more stable. There was no advantage to investigating a specific phenotype ( Figure 2) ; therefore, results from all three meta-analyses were considered.
The emphasis in this study was on SNPs located within genes. Genic information for all SNPs was retrieved from the National Center for Biotechnology Information's dbSNP browser using Build 37.1. Genic associations were retained if more than one SNP had a significant association (Po0.05). Two pathway analyses were conducted using genes with at least one association at the Po0.001 level in any of the three meta-analyses using WebGestalt v.2 (http://bioinfo.vanderbilt.edu/ webgestalt/). 64 Of the 441 genes submitted for analysis, 424 were incorporated for analysis using a hypergeometric test to compare the submitted list to a reference of all human genes. Genes excluded were primarily predicted/hypothetical loci with no known function. The first analysis of Kyoto Encyclopedia of Genes and Genomes pathways was restricted to pathways where at least two genes were present in the submitted list. The second analysis was restricted to investigating Gene Ontology terms.
